You are here

Celgene

How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4

How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4

Motley Fool

Bristol-Myers Squibb

Flag link:

Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug

Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug

Endpoints

Bristol-Myers Squibb

ulcerative colitis

priority review

Flag link:

FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020

FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020

Fierce Pharma

Bristol-Myers Squibb

Flag link:

BMS/Celgene merger payout evaporates as CVR deadline passes

BMS/Celgene merger payout evaporates as CVR deadline passes

Pharmaforum

Bristol-Myers Squibb

Flag link:

An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution

An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution

Endpoints

Bristol-Myers Squibb

drug manufacturing

Flag link:

Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

Endpoints

Bristol-Myers Squibb

Flag link:

Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches

Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches

Fierce Pharma

Bristol-Myers Squibb

Flag link:

[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions

[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions

Motley Fool

Bristol-Myers Squibb

Flag link:

Celgene shareholders are parsing blurry photos in search of a payday

Celgene shareholders are parsing blurry photos in search of a payday

Stat

Bristol-Myers Squibb

Flag link:

Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity

Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity

Xconomy

Bristol-Myers Squibb

clinical trials

clinical trial diversity

Flag link:

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

RAPS.org

Teva Pharmaceutical

Flag link:

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

Fierce Pharma

Bristol-Myers Squibb

Teva Pharmaceutical

Flag link:

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

Fierce Biotech

Bristol-Myers Squibb

priority review

Flag link:

Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms

Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms

Endpoints

Flag link:

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

Fierce Pharma

Flag link:

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Fierce Pharma

Flag link:

After Celgene deal, BMS shoots up pharma market cap rankings

After Celgene deal, BMS shoots up pharma market cap rankings

Pharmaforum

Bristol-Myers Squibb

Flag link:

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

BioSpace

triple negative breast cancer

clinical trials

Flag link:

Bristol's Celgene merger sees it bounce Jounce drug pact

Bristol's Celgene merger sees it bounce Jounce drug pact

Fierce Biotech

Bristol-Myers Squibb

Jounce Therapeutics

immuno-oncology

Flag link:

Bristol Myers Squibb's Zeposia launches into crowded MS market

Bristol Myers Squibb's Zeposia launches into crowded MS market

Fierce Pharma

Bristol-Myers Squibb

multiple sclerosis

Flag link:

Pages